Pharmacotherapy for male breast cancer

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 6, 2002, Pages 701-708

  Hayes, Teresa ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Hormonal therapy; Male breast cancer; Orchiectomy; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; CALUSTERONE; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GLUCOCORTICOID; GONADORELIN DERIVATIVE; KETOCONAZOLE; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; PREDNISONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN CITRATE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENALECTOMY; AFFECTIVE NEUROSIS; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CATARACT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEMINIZATION; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MALE BREAST; METASTASIS; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; REVIEW; VEIN THROMBOSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECT; GENETICS; PATHOLOGY; RISK FACTOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 0036072893     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.6.701     Document Type: Review

References (128)

1. Cancer statistics, 2002
2. BRCA2 mutations among Hungarian male breast cancer patients without family history
3. On bilharziasis and male breast cancer in Egypt
4. Carcinoma of the male breast in Zambia
5. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors
6. Male breast cancer (MBC) in the SEER database
7. Breast cancer in men
8. Cancer of the male breast
9. Male breast cancer: A review of the literature
10. Breast cancer in men
11. The sex hormone profile of male patients with breast cancer
12. Male breast carcinoma following estrogen therapy: Report of a case
13. Report of two cases of male breast cancer after prolonged estrogen treatment for prostatic carcinoma
14. Breast cancer in a trans-sexual man receiving hormone replacement therapy
15. Breast cancer in a male-to-female transsexual - A case report
16. Carcinoma of the breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics
17. Carcinoma of the breast and Klinefelter's syndrome
18. Male breast cancer. III. Breast carcinoma in association with the Klinefelter syndrome
19. Prevalence of Klinefelter's syndrome in male breast cancer patients
20. BRCA2 germline mutations in male breast cancer cases and breast cancer families
21. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population
22. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
23. Study of a single BRCA2 mutation with high carrier frequency in a small population
24. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer
25. BRCA2 germ line mutations are frequent in male breast cancer patients without a family history of the disease
26. Disorders of the testes
27. The adrenal cortex
28. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age
29. Role of aromatase in sex steroid action
30. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men
31. Nonsteroidal and steroidal aromatase inhibitors in breast cancer
32. Aromatase expression and its localization in human breast cancer
33. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: An immunohistochemical study
34. Molecular markers in male breast carcinoma
35. Hormone receptors in male breast carcinoma
36. Detection of the estrogen receptor and response to endocrine therapy in male breast cancer patients
37. Clinical correlations of steroid receptors and male breast cancer
38. Estrogen receptors in male breast cancer
39. Hormone receptors in male breast cancer
40. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer
41. Cancer of the male breast
42. Male breast carcinoma: Clinical experience in a suburban community
43. Male breast cancer: R7esults of the treatments and prognostic factors in 397 cases
44. Cancer of the male breast: A review
45. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas
46. Proliferative activity and steroid hormone receptor status in male breast carcinoma
47. Androgen receptor expression in male breast carcinoma: Lack of clinicopathological association
48. Clinical relevance of biologic factors in male breast cancer
49. Carcinoma of the breast in males: A multi-institutional survey
50. Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
51. Angiogenesis, p53 and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer
52. c-erbB2 and p53 overexpression as predictors of survival in patients with male breast cancer
53. Steroid receptor distribution in 47 892 breast cancers. A collaborative study of 7 European laboratories
54. Estrogen and progesterone receptors: Comparison in age-matched men and women with breast cancer
55. Male breast carcinoma. II. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to treatment, prognostic factors and survival
56. Treatment of advanced male breast cancer
57. The role of orchiectomy in the management of advanced male breast cancer
58. The treatment of cancer, especially inoperable cancer of the male breast, by ablative surgery (orchidectomy, adrenalectomy and hypophysectomy) and hormone therapy (oestrogens and corticosteroids); an analysis of 42 patients
59. Hormonal therapy for metastatic male breast cancer
60. Cyproterone acetate in advanced male breast cancer
61. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: A case report
62. Male breast cancer
63. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide
64. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer
65. Hypophysectomy in the treatment of advanced cancer of the male breast
66. Hormonal treatment of disseminated male breast cancer
67. Role of aminoglutethimide in male breast cancer
68. Ketoconazole for male metastatic breast cancer
69. Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy
70. Metastatic breast cancer in males. Assessment of endocrine therapy
71. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast
72. High-dose medroxyprogesterone acetate in advanced male breast cancer
73. Response to megestrol in male breast carcinoma
74. Male breast cancer
75. Hormonal therapy with tamoxifen in male breast cancer
76. Tamoxifen and male breast cancer
77. Tamoxifen in advanced male breast cancer
78. Use of tamoxifen in advanced male breast cancer
79. Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: A case report
80. A 94 year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation
81. A case of brain metastases from male breast cancer responding to tamoxifen
82. A case report of advanced male breast cancer with an objective response to tamoxifen treatment
83. Adjuvant tamoxifen for male breast cancer (MBC)
84. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients
85. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: M.D. Anderson Cancer Center Experience
86. Pharmacological and clinical profile of anastrozole
87. Oestrogen suppression in males: Metabolic effects
88. Male breast cancer: Two cases with objective regression from calusterone (7α, 17β-dimethyltestosterone) after failure of orchiectomy
89. Carcinoma of the male breast
90. Chemotherapy for advanced male breast cancer
91. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
92. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients
93. Chemotherapy in metastatic male breast cancer
94. Adriamycin combinations in advanced breast cancer: A Southwest Oncology Group study
95. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
96. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer
97. Comparison of induction chemotherapies for metastatic breast cancer: An Eastern Cooperative Oncology Group trial
98. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized Phase III multicenter trial
99. Cancer of the male breast
100. Trastuzumab and breast cancer
101. Tamoxifen for early breast cancer: An overview of the randomised trials
102. Adjuvant chemotherapy in males with cancer of the breast
103. Role of adjuvant chemotherapy in male breast cancer
104. Therapy and survival in male breast carcinoma: A retrospective analysis of 50 cases
105. Carcinoma of the male breast: A review of adjuvant therapy
106. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
107. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
108. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy
109. ICI 182,780 (Faslodex™) for the treatment of advanced breast cancer in postmenopausal women - Prospective combined analysis of two multicenter trials
110. Male breast cancer: A clinicopathologic study of 97 cases
111. Male breast carcinoma: Review of a multicenter series of 150 cases
112. Prognosis of breast cancer in males: An analysis of 170 cases
113. Differences between male and female breast cancer. III. Prognostic features
114. Male breast cancer: A 22-year experience
115. Carcinoma of the male breast: Report of a series of 88 cases
116. Male breast cancer: A 13-year review of 89 patients
117. The prognosis of breast cancer in males. A report of 335 cases
118. Breast cancer in the man: A report of 30 patients
119. A comparison outcome of male breast cancer with female breast cancer
120. Carcinoma of the male breast: Analysis of prognosis compared with matched female patients
121. Carcinoma of the male breast: A review and recommendations for management
122. Stages at presentation, prognostic factors and outcome of breast cancer in males
123. Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996
124. Male breast cancer. Does the prognosis differ compared to female?
125. A retrospective study of male breast cancer in Holland
126. Male breast cance - A reappraisal of clinical and biologic indicators of prognosis
127. Differences between male and female breast cancer. II. Clinicopathologic features
128. Prognostic variables in male breast cancer